Skip to content
Trial Eligibility
Menu

A Study of Brenipatide in Participants With Major Depressive Disorder

NCT07928245

This study is recruiting at 2 US sites in 2 states, according to its ClinicalTrials.gov record last updated .

Summary

This study evaluates the safety and efficacy of brenipatide (LY3537031) as an add on therapy in participants with major depression who still have symptoms while taking a stable dose of standard of care anti-depressant medicine. The study will last approximately 5 months.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Major Depressive Disorder

Eligibility basics and study details

Study type
Interventional
Phase
Phase 2
Ages
18 to 75 years
Sex
All
Healthy volunteers
Not accepted
Sponsor
Eli Lilly and Company
Last updated on ClinicalTrials.gov
November 20, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

California · 1

  • Inland Psychiatric Medical Group · Chino, CA

Florida · 1

  • Denali Health - Plant City, FL · Plant City, FL

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.